Glenmark Builds US OTC Lineup In Wockhardt Deal

Glenmark acquires a portfolio of generic OTCs from Wockhardt marketed in US including famotidine 10- and 20-mgs; cetirizine 5- and 10-mgs; lansoprazole 15-mg delayed-release; and olopatadine hydrochloride 0.1% ophthalmic solution.

• Source: Shutterstock

Indian pharma Glenmark Pharmaceuticals moves to further expand its OTC business in the US by striking a deal with Wockhardt to acquire a portfolio of generic equivalents of brand products.

Financial details of the transaction were not disclosed. Glenmark indicated only that it “continues to expand its OTC portfolio with the acquisition" of Wockhardt's approved abbreviated new drug applications.

More from Deals

More from Business